Principal objective is to evaluate the impact of Thalidomide to prolong the duration of response after autologous transplantation for myeloma

Inclusion Criteria:

• de novo myeloma
• according to Durie and Salmon classification stage II, III and stage I with a lytic bone lesion
• patients from 18 to 65 years old
• beta2microglobulin < 3 mg/l or del13 absent
• signed informed consent
• eligible for transplantation

Exclusion Criteria:

• peripheral neurological toxicities
• uncontrolled or severe cardiovascular disease
• other malignancy except basocellular carcinoma or FIGO stage I carcinoma of the cervix
• patient who received biphosphonate during the last 60 days
• renal failure definited as creatinine > 150 µmol/l
• patient with obvious vascular cerebral medical history
• liver dysfunction definited as bilirubin > 35 µmol/l or ASAT, ALAT, PAL > 4N
• respiratory dysfunction
• HIV +
• Patient who refused to use an acceptable barrier method for contraception